Concurrent treatment with transarterial immunoembolization of hepatic metastases and systemic immune checkpoint inhibitors to overcome immune evasion in patients with metastatic uveal melanoma
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04124-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Natalie J Miller und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Melanoma, Uveal Neoplasms, Liver Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Jacob Green Foundation, National Cancer Institute.
Abstract (Originalsprache)
Background
Metastatic uveal melanoma (mUM) is an uncommon melanoma subtype, poorly immunogenic with low objective response rates (ORR) to immune checkpoint inhibitors (ICI). Liver-directed therapies (LDT) are commonly used given the strong predilection for hepatic metastases. Transarterial immunoembolization (TAIE) with granulocyte–macrophage colony stimulating factor (GM-CSF) can potentially synergize with concurrent systemic ICI to overcome immune evasion.
Methods
This single-center, retrospective study includes mUM patients with liver-predominant metastases who received TAIE, with/without concurrent systemic ICI (≤ 3 months before/during TAIE). Endpoints included ORR, progression-free survival (PFS), overall survival (OS), and adverse events (AEs).
Results
Between 2016 and 2023, 18 mUM patients (median age 64 years) received TAIE (median 4 procedures/patient). Fourteen patients (78%) received concurrent ICI. ORR was 17% (3/18), all in patients receiving ICI, with partial responses lasting 4.2, 35 + and 46 months. Disease control rate (stable disease or better) was 56% (10/18). Median time to next systemic therapy or death was 19.5 months (range 1.6- 46). Median PFS and OS from first TAIE treatment were 4.9 months (range 0.7–46) and 35 months (range 1.7- 46). Immune-related AEs (IRAE) during concurrent therapy occurred in seven of 10 patients receiving anti-CTLA-4/PD-1 combination, including hepatitis (n = 5; grade 2 in 1, grade 3 in 4). Four of seven patients resumed anti-PD-1 monotherapy without recurrent IRAE.
Conclusions
Concurrent LDT with GM-CSF TAIE and ICI, including anti-CTLA-4/PD-1 combination, is feasible, safe, and can lead to sustained clinical benefit in a subset of mUM patients. OS with this combination compares favorably to published outcomes for systemic therapy or LDT alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Washington, Seattle, WA, USA.
- Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Colorado Permanente Medical Group, Denver, CO, USA.
- University of Washington, Seattle, WA, USA. sbhatia@uw.edu.
- Fred Hutchinson Cancer Center, Seattle, WA, USA. sbhatia@uw.edu.
Förderung
- NCI NIH HHS
- Jacob Green Foundation
- National Cancer Institute
Zitieren
APA
Miller, N. J., Kwan, S. W., Leary, J. B., Hippe, D. S., McCamy, W., Veatch, J. R., Hall, E. T., Monsky, W. L., & Bhatia, S. (2025). Concurrent treatment with transarterial immunoembolization of hepatic metastases and systemic immune checkpoint inhibitors to overcome immune evasion in patients with metastatic uveal melanoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04124-x
Vancouver
Miller NJ, Kwan SW, Leary JB, Hippe DS, McCamy W, Veatch JR, et al. Concurrent treatment with transarterial immunoembolization of hepatic metastases and systemic immune checkpoint inhibitors to overcome immune evasion in patients with metastatic uveal melanoma. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04124-x
BibTeX
@article{Miller2025,
author = {Miller, Natalie J and Kwan, Sharon W and Leary, Jacob B and Hippe, Daniel S and McCamy, William and Veatch, Joshua R and Hall, Evan T and Monsky, Wayne L and Bhatia, Shailender},
title = {Concurrent treatment with transarterial immunoembolization of hepatic metastases and systemic immune checkpoint inhibitors to overcome immune evasion in patients with metastatic uveal melanoma},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04124-x}
}
EUVIMED